These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31599951)

  • 21. Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment.
    Murao N; Ohge H; Ikawa K; Watadani Y; Uegami S; Shigemoto N; Shimada N; Yano R; Kajihara T; Uemura K; Murakami Y; Morikawa N; Sueda T
    Int J Antimicrob Agents; 2017 Sep; 50(3):393-398. PubMed ID: 28694230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units.
    Wong G; Brinkman A; Benefield RJ; Carlier M; De Waele JJ; El Helali N; Frey O; Harbarth S; Huttner A; McWhinney B; Misset B; Pea F; Preisenberger J; Roberts MS; Robertson TA; Roehr A; Sime FB; Taccone FS; Ungerer JP; Lipman J; Roberts JA
    J Antimicrob Chemother; 2014 May; 69(5):1416-23. PubMed ID: 24443514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations.
    Udy AA; Varghese JM; Altukroni M; Briscoe S; McWhinney BC; Ungerer JP; Lipman J; Roberts JA
    Chest; 2012 Jul; 142(1):30-39. PubMed ID: 22194591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: A retrospective analysis on pharmacokinetics and pharmacokinetic target attainment.
    Chiriac U; Frey OR; Roehr AC; Koeberer A; Gronau P; Fuchs T; Roberts JA; Brinkmann A
    Medicine (Baltimore); 2021 Jun; 100(22):e26253. PubMed ID: 34087915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
    Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
    Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy.
    Bue M; Sou T; Okkels ASL; Hanberg P; Thorsted A; Friberg LE; Andersson TL; Öbrink-Hansen K; Christensen S
    Int J Infect Dis; 2020 Mar; 92():133-140. PubMed ID: 31978581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review of optimal pharmacokinetic/pharmacodynamic parameters for beta-lactam therapy in infective endocarditis.
    Robson C; Tan B; Stuart R; Nicholls S; Rogers BA; Sandaradura I
    J Antimicrob Chemother; 2023 Mar; 78(3):599-612. PubMed ID: 36691839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beta-lactam target attainment and associated outcomes in patients with bloodstream infections.
    Alshaer MH; Maranchick N; Alexander KM; Manigaba K; Shoulders BR; Felton TW; Mathew SK; Peloquin CA
    Int J Antimicrob Agents; 2023 Mar; 61(3):106727. PubMed ID: 36646230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
    Grau S; Lozano V; Valladares A; Cavanillas R; Xie Y; Nocea G
    Appl Health Econ Health Policy; 2015 Aug; 13(4):369-79. PubMed ID: 25761545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients.
    Martínez-Casanova J; Esteve-Pitarch E; Colom-Codina H; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Padullés-Zamora A
    Antibiotics (Basel); 2023 Mar; 12(3):. PubMed ID: 36978398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia.
    Alshaer MH; Maranchick N; Bai C; Maguigan KL; Shoulders B; Felton TW; Mathew SK; Mardini MT; Peloquin CA
    Antimicrob Agents Chemother; 2022 Jul; 66(7):e0056322. PubMed ID: 35699444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Personalised antibiotic therapy in a surgical intensive care unit overview of current knowledge and the results of an observational kinetic study].
    Kaška M; Martinková J; Havel E; Kočí J; Fousková A; Solichová D; Kujovská L; Selke-Krulichová I; Práznovec I; Salavec V
    Rozhl Chir; 2014 Sep; 93(9):456-62. PubMed ID: 25301344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
    Solomkin JS; Yellin AE; Rotstein OD; Christou NV; Dellinger EP; Tellado JM; Malafaia O; Fernandez A; Choe KA; Carides A; Satishchandran V; Teppler H;
    Ann Surg; 2003 Feb; 237(2):235-45. PubMed ID: 12560782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.
    Sinnollareddy MG; Roberts MS; Lipman J; Roberts JA
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):489-96. PubMed ID: 22519600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections.
    De Pascale G; Lisi L; Ciotti GMP; Vallecoccia MS; Cutuli SL; Cascarano L; Gelormini C; Bello G; Montini L; Carelli S; Di Gravio V; Tumbarello M; Sanguinetti M; Navarra P; Antonelli M
    Ann Intensive Care; 2020 Jul; 10(1):94. PubMed ID: 32661791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
    Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
    Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course.
    Carlier M; Carrette S; Stove V; Verstraete AG; De Waele JJ
    Int J Antimicrob Agents; 2014 May; 43(5):470-3. PubMed ID: 24685990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study.
    Huttner A; Von Dach E; Renzoni A; Huttner BD; Affaticati M; Pagani L; Daali Y; Pugin J; Karmime A; Fathi M; Lew D; Harbarth S
    Int J Antimicrob Agents; 2015 Apr; 45(4):385-92. PubMed ID: 25656151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients.
    Abdulla A; Ewoldt TMJ; Purmer IM; Muller AE; Gommers D; Endeman H; Koch BCP
    Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):359-368. PubMed ID: 33463382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.